MX2018013325A - Derivados de adenina como inhibidores de proteína quinasa. - Google Patents

Derivados de adenina como inhibidores de proteína quinasa.

Info

Publication number
MX2018013325A
MX2018013325A MX2018013325A MX2018013325A MX2018013325A MX 2018013325 A MX2018013325 A MX 2018013325A MX 2018013325 A MX2018013325 A MX 2018013325A MX 2018013325 A MX2018013325 A MX 2018013325A MX 2018013325 A MX2018013325 A MX 2018013325A
Authority
MX
Mexico
Prior art keywords
protein kinase
pharmaceutically acceptable
formula
diseases
compound
Prior art date
Application number
MX2018013325A
Other languages
English (en)
Inventor
Surleraux Dominique
Amiable Claire
Guillon Rémi
Original Assignee
B C I Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B C I Pharma filed Critical B C I Pharma
Publication of MX2018013325A publication Critical patent/MX2018013325A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente invención se refiere a un compuesto adecuado para usarse como un inhibidor de cinasa de conformidad con la fórmula general (I) [compuesto (C), en lo sucesivo], o el N-óxido, sal farmacéuticamente aceptable, solvato farmacéuticamente aceptable, o estereoisómero del mismo, fórmula (I) en donde A, R1, R2, R3, R3', R4, R4', X, Y, Z, T son como se define en las reivindicaciones; la invención además se refiere a un método in vitro para inhibir actividad de proteína cinasa que comprende poner en contacto una proteína cinasa con un compuesto de la fórmula (I), o el N-óxido, sal farmacéuticamente aceptable, solvato farmacéuticamente aceptable, o estereoisómero del mismo; la invención además se refiere a los compuestos de la fórmula (I) por sí mismos, así como a su uso como un medicamente, y para usarse o en un método de tratamiento de una enfermedad mediada por una proteína cinasa seleccionada de cáncer, trastornos inflamatorios, enfermedades cardiovasculares, enfermedades inducidas virales, enfermedades circulatorias, enfermedades fibro-proliferativas y trastornos de sensibilización al dolor. (ver fórmula I).
MX2018013325A 2016-05-04 2017-05-04 Derivados de adenina como inhibidores de proteína quinasa. MX2018013325A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305530 2016-05-04
PCT/EP2017/060730 WO2017191297A1 (en) 2016-05-04 2017-05-04 Adenine derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2018013325A true MX2018013325A (es) 2019-08-16

Family

ID=55953089

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013325A MX2018013325A (es) 2016-05-04 2017-05-04 Derivados de adenina como inhibidores de proteína quinasa.

Country Status (14)

Country Link
US (1) US11236093B2 (es)
EP (1) EP3452477B1 (es)
JP (1) JP2019516688A (es)
KR (1) KR102479746B1 (es)
CN (1) CN109311882B (es)
AU (1) AU2017260298B9 (es)
BR (1) BR112018072468A2 (es)
CA (1) CA3022896A1 (es)
EA (1) EA201892460A1 (es)
IL (1) IL262700B (es)
MX (1) MX2018013325A (es)
SG (1) SG11201809674QA (es)
WO (1) WO2017191297A1 (es)
ZA (1) ZA201808014B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6920411B2 (ja) * 2016-07-25 2021-08-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ
JP2020523362A (ja) * 2017-06-14 2020-08-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ 治療への使用のための二環式複素芳香族尿素またはカルバメート化合物
US20220288087A1 (en) * 2019-04-30 2022-09-15 City University Of Hong Kong Pim1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof
EP4006028A4 (en) 2019-07-26 2022-09-14 Zhuhai Yufan Biotechnologies Co., Ltd IRAK4 KINASE INHIBITOR AND METHOD FOR PREPARING IT
CN111560389B (zh) * 2020-06-11 2022-07-01 云南中烟工业有限责任公司 烟草丝裂原活化蛋白激酶基因NtMAPK8及其应用
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9010404D0 (en) * 1990-05-09 1990-06-27 Pfizer Ltd Therapeutic agents
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
AU2006297351A1 (en) * 2005-09-30 2007-04-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
JPWO2010119875A1 (ja) * 2009-04-14 2012-10-22 アステラス製薬株式会社 縮合ピロロピリジン誘導体
EP2508607A1 (en) * 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
US9889180B2 (en) * 2012-11-19 2018-02-13 Agency For Science, Technology And Research Method of treating cancer
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS

Also Published As

Publication number Publication date
IL262700A (en) 2018-12-31
CA3022896A1 (en) 2017-11-09
EA201892460A1 (ru) 2019-09-30
IL262700B (en) 2022-02-01
KR102479746B1 (ko) 2022-12-21
BR112018072468A2 (pt) 2019-02-19
WO2017191297A1 (en) 2017-11-09
ZA201808014B (en) 2020-02-26
CN109311882A (zh) 2019-02-05
US20190127379A1 (en) 2019-05-02
AU2017260298A1 (en) 2018-12-13
US11236093B2 (en) 2022-02-01
CN109311882B (zh) 2022-02-11
SG11201809674QA (en) 2018-11-29
KR20190003968A (ko) 2019-01-10
EP3452477C0 (en) 2023-09-13
EP3452477A1 (en) 2019-03-13
EP3452477B1 (en) 2023-09-13
AU2017260298B9 (en) 2021-09-30
AU2017260298B2 (en) 2021-09-02
JP2019516688A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
SA520411325B1 (ar) مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
CR20200441A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MX2023001876A (es) Derivados de rapamicina.
NZ764151A (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
SG10201903579SA (en) Indole carboxamides compounds useful as kinase inhibitors
PL415078A1 (pl) Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
MX2021007247A (es) Derivados de rapamicina.